Inspire Pharmaceuticals — Investor Day (March 2006)
105 slides from Inspire Pharmaceuticals's investor day presentation, Mar 21, 2006
Slide 1: Inspire
INSPIRE
Slide 2: Inspire R&D Investor Meeting – March 21, 2006
Christy L. Shaffer, Ph.D. President and Chief Executive Officer Inspire Pharmaceuticals Inspire R&D Investor Meeting – March 21, 2006
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995 which convey management’s expectations, beliefs, plans and objectives regarding future performance. These statements discuss matters that are not facts,
Slide 4: R&D Investor Meeting Agenda
Inspire R&D Investor Meeting Agenda Corporate Overview Scientific Overview of Cystic Fibrosis (CF) CF Program Overview Scientific Overview of Allergy Intranasal Epinastine Program Overview INS50589 Program Overview Christy Shaffer, Ph.D. Richard Boucher, M.D. Lynn Smiley, M.D. William Berger, M.D.,
Slide 5: Balanced Product Portfolio
Balanced Product Portfolio Product Diquafosol tetrasodium Denufosol tetrasodium INS50589 Antiplatelet Intranasal epinastine Outflow enhancer Elestat® Restasis® Indication Dry Eye Cystic Fibrosis Acute Cardiac Care Seasonal Allergic Rhinitis Glaucoma Allergic Conjunctivitis Dry Eye Status Approvable(
Slide 6: Financial Overview
Financial Overview Receiving co-promotion revenues on Elestat® and Restasis® Potential to achieve revenues from out-licensing deals, including potential additional milestone payments from Allergan $122 million cash balance at 12/31/05 2006 Guidance* Aggregate revenue—$31 to $39 million Operating exp
Slide 7: Focused Strategy to Leverage Technology and Build Portfolio
Focused Strategy to Leverage Technology and Build Portfolio Key Therapeutic Areas of Focus Driven by in-house science/technology Enhanced through in-house research and strategic partnerships Ophthalmology Diquafosol tetrasodium (P2Y2 agonist) Elestat® Restasis® Glaucoma Respiratory / Allergy Denufos
Slide 8: Creating Successful Collaborations
Creating Successful Collaborations Inspire R&D Investor Meeting – March 21, 2006
Slide 9: Overview of Cystic Fibrosis
Overview of Cystic Fibrosis Richard C. Boucher, M.D. Kenan Professor of Medicine Director, CF/Pulmonary Research and Treatment Center University of North Carolina at Chapel Hill
Slide 10: Disclosure
Disclosure The presenter is a co-founder of Inspire Pharmaceuticals and has served as a consultant and clinical investigator for Inspire. The presenter owns stock and stock options in Inspire Pharmaceuticals.
Slide 11: Cystic Fibrosis: A multi-system disease
Cystic Fibrosis: A multi-system disease The most common lethal genetic disease of children The abnormal CF gene was identified in 1989 More than 95% of CF patients die of lung infection
Slide 12: Mucus Transport is the Primary Lung Defense Mechanism
Mucus Transport is the Primary Lung Defense Mechanism-and It Fails in Cystic Fibrosis
Slide 13: Mucus Clearance and Cystic Fibrosis Pathogenesis
Mucus Clearance and Cystic Fibrosis Pathogenesis: Role of Airway Surface Hydration Normal Lung CF Lung Normal Cystic Fibrosis
Slide 14: The in Vitro Model System
The in Vitro Model System that Enabled the Study of Airways Defense
Slide 15: The Model System Maintains Mucus Transport in Vitro
The Model System Maintains Mucus Transport in Vitro Note: This slide contains a video clip that is not available in PDF format or webcast.
Slide 16: The Study of ASL Volume and Mucus Transport
The Study of ASL Volume (Hydration) and Mucus Transport Microelectrodes (Vt) T-Col Chamber Mucus Transport Laser Scanning Confocal Microscopy Ringer Perfluorocarbon (PFC) ASL CELLS PFC + Compound
Slide 17: Normal but not CF Airway Epithelia Regulate Surface Hydration
Under Standard Laboratory Conditions (Static), Normal but not CF Airway Epithelia Regulate Surface Hydration/Mucus Transport NL CF Normal 7 ?m CF
Slide 18: Adenosine Regulates ASL Height
Adenosine, Generated from ATP Release, Regulates ASL Height
Slide 19: Adenosine Regulates ASL Volume Homeostasis
Adenosine Regulates ASL Volume Homeostasis in Normal but not CF Airway Epithelia NL [ADO] = 100 ± 19 nM (n=10) CF [ADO] = 189 ± 71 nM (n=3) Control (9) 8-SPT (5) Control (8) 8-SPT (6) 8-SPT = Adenosine Receptor Antagonist
Slide 20: Mucus Transport is Preserved in Normal Cultures
Mucus Transport is Preserved for Long Periods of Time in Normal Cultures T = 0 T = 24 hour
Slide 21: In CF, Mucus Transport Fails
In CF, Mucus Transport Fails, and Mucus Adheres to Airway Surfaces T = 0 T = 24 hour
Slide 22: Adherent Mucus In CF: Beautiful but Deadly
Adherent Mucus In CF: Beautiful but Deadly Mucus Plaque Epithelium
Slide 23: Discrepancy Between CF Mucus Clearance Rates In Vitro vs In Vivo
Discrepancy Between CF Mucus Clearance Rates In Vitro vs In Vivo NL CF NL CF In Vitro: Matsui et al., Cell, 1998 In Vivo: Robinson et al., J. Aerosol. Med. 2000 Mucus Transport (%) Mucus Clearance (?m/s)
Slide 24: CF Produces Heterogeneous Lung Defects
CF Produces Heterogeneous Structural and Mucus Clearance Lung Defects
Slide 25: In Vitro Modeling of Phasic Motion and Shear Stress
In Vitro Modeling of the Phasic Motion and Shear Stress Associated with Respiration shear = h r t Where: p= density h = ASL height q= angular velocity r = distance from the center of rotation t = time of acceleration
Slide 26: Phasic Motion Maintains CF ASL Height
Phasic Motion Maintains CF ASL Height
Slide 27: Phasic Motion Maintains CF Mucus Transport
Phasic Motion Maintains CF Mucus Transport Static: Phasic Motion: both n = 12
Slide 28: ATP as a Candidate Molecule to Rebalance CF Ion Transport
ATP as a Candidate Molecule to Rebalance CF Ion Transport under Phasic Motion
Slide 29: Direct Biochemical Measurements of ATP During Phasic Motion
Direct Biochemical Measurements of [ATP] During Phasic Motion ASL [ATP] Serosal [ATP]
Slide 30: ATP Mediates the CF Phasic Motion Response
ATP Mediates the CF Phasic Motion Response Control Apyr. (shear)
Slide 31: NL vs CF ASL Homeostasis
NL vs CF ASL Homeostasis – NLs Possess Dual Regulation (ATP; ADO), whereas CF Relies Solely on ATP NL CF
Slide 32: RSV Infection Abolishes Shear-Mediated ASL Homeostasis
Respiratory Syncitial Virus (RSV) Infection Abolishes Shear-Mediated ASL Homeostasis in CF Airways
Slide 33: ATP Hydrolysis by eNPPs Upregulated in CF Airways
ATP Hydrolysis by eNPPs is Upregulated in CF Airways During RSV Infections N.B., Ap4A is an eNPP-specific substrate
Slide 34: Viral Infection Exacerbates Disease
Viral Infection Exacerbates Disease Via Slowing Mucus Clearance Baseline Insult (virus) Exacerbation (bacterial)
Slide 35: How Do You Restore ASL Volume and Mucus Clearance
How Do You Restore ASL Volume and Mucus Clearance in CF Therapeutically? Add Salt. Osmotically: HS Pharmacologically: ATP/UTP t (min) t (min) ASL Height (?m) 40 35 30 25 20 15 10 5 0 HS ASL Height (?m) 20 15 10 5 0
Slide 36: Aerosol Physics: Limitation to Inhaled Osmolytes
Aerosol Physics: Limitation to Inhaled Osmolytes
Slide 37: Generation of Dinucleotide Compounds
Generation of Dinucleotide Compounds to Extend Duration of Activity by Reducing Rate of Ecto-Metabolism INS37217 INS365 UTP Nucleotide hydrolysis (%) 100 80 60 40 20 0 0 10 20 30 40 50 60 Time (min) Inspire Pharmaceuticals
Slide 38: Treating Superficial Epithelial Volume Deficit
Treating Superficial Epithelial Volume Deficit Can Improve CF Lung Disease INS37217 Baseline Virus INS37217 Modest FEV1/FEF25-75% Large Exacerbations Large MC
Slide 39: Denufosol Tetrasodium: A Potential Breakthrough
Denufosol Tetrasodium: A Potential Breakthrough 08-103 Inspire Trial Summary of Spirometry Results Significant differences1 in favor of active doses (pooled) for all 4 spirometry parameters FEV1 (max): p-value = 0.006 FEF25%-75% : p-value = 0.008 FVC (max): p-value = 0.022 FEV1 /FVC : p-value = 0.04
Slide 40: Consistent Effects in Patients With Mild CF Lung Disease
Denufosol Has Shown Consistent Effects in Patients With Mild CF Lung Disease Difference From Placebo In Percent Change From Baseline To End Of Study In Patients With 75% Predicted Normal FEV1 At Baseline 08-102 N=33 08-103 N=89 08-104 N=24* 9% 8% 7% 6% 5% 4% 3% 2% 1% 0% FEV1 FEF25%-75% FEV1 FEF25%-7
Slide 41: Reductions in Pulmonary Exacerbations
Reductions in Pulmonary Exacerbations 08-103 N=89 08-104 N=67 14% 12% 10% 8% 6% 4% 2% 0% placebo N=21 denufosol N=68 placebo N=23 denufosol N=44 Inspire Pharmaceuticals
Slide 42: Re-hydration Therapies May Prevent Progression of CF
Re-hydration Therapies May Prevent Progression of CF Lung Disease Preventative Therapy (e.g., INS37217) 100% Lung Function 25% Rescue Therapy Age (yrs) Inspire Pharmaceuticals
Slide 43: Overview of Cystic Fibrosis
Overview of Cystic Fibrosis Richard C. Boucher, M.D. Kenan Professor of Medicine Director, CF/Pulmonary Research and Treatment Center University of North Carolina at Chapel Hill
Slide 44: M. Lynn Smiley, M.D.
M. Lynn Smiley, M.D. Chief Medical Officer Inspire Pharmaceuticals Inspire R&D Investor Meeting – March 21, 2006
Slide 45: Regulatory Status of Denufosol Tetrasodium
Regulatory Status of Denufosol Tetrasodium Advancing to Phase 3 based on Phase 1 & 2 safety and efficacy findings and completion of End-of-Phase 2 FDA meeting U.S. and European Union Orphan Drug designation Fast track status in U.S. European Medicines Agency (EMEA) protocol assistance process initia
Slide 46: Overview of Clinical Development Program to Date
Overview of Clinical Development Program to Date Over 300 patients/volunteers studied in 6 completed clinical trials Phase 1 trial (volunteers) 08-101 Phase 2 trials (CF patients) Dose-ranging nasal potential difference study (UNC) 08-102 08-103 08-104 2 PK studies (volunteers) 08-105 08-106 Inspire
Slide 47: Demographics and Baseline Characteristics
Demographics and Baseline Characteristics in Phase 2 Study 08-102 All Groups Combined N=61 Study 08-103 All Groups Combined N=89 Study 08-104 All Groups Combined N=72 Mean age, years 18.8 16.1 21.2 FEV1 % predicted 79.1 93.0 75.5 FEF25-75% % predicted 61.2 78.2 49.0 Patients requiring hospitalizatio
Slide 48: Safety Summary Across Phase Trials
Safety Summary Across Phase 2 Trials Denufosol (up to 60 mg) was generally well tolerated, especially in CF patients with less severe lung function impairment Cough was most frequently reported adverse event Slight transient decline in lung function was noted immediately following administration of
Slide 49: Phase 3 Program: TIGER
Phase 3 Program TIGER : Transport of Ions to Generate Epithelial Rehydration R&D Investor Meeting – March 21, 2006
Slide 50: Global Phase 3 Program: Initial Indication for Early Intervention
Global Phase 3 Program: Initial Indication for Early Intervention Tiger-1 trial – targeting mid-year 2006 initiation Tiger-2 trial – 1st Half 2007 projected start One 2-year carcinogenicity study required (3 years to complete) Patients with early CF lung disease – FEV1> 75% predicted Primary endpoin
Slide 51: Centralized Spirometry Helps Reduce Data Variability
Centralized Spirometry Helps Reduce Data Variability FEV1 (L): Absolute Change Between Visits | Screening—Visit 1 Pre-Dose | 0.0 0.1 0.2 0.3 0.4 0.5 0.6 Inspire Phase II With Over-Read Inspire Phase II Historical CH Goss, et al., NACF 2004 Inspire R&D Investor Meeting – March 21, 2006
Slide 52: Tiger-1 Trial Sites
Tiger-1 Trial Sites: > 70 Sites Recruited Cystic Fibrosis Foundation’s Therapeutics Development Network (TDN) sites Inspire R&D Investor Meeting – March 21, 2006
Slide 53: Summary: Denufosol tetrasodium for Cystic Fibrosis
Summary Denufosol tetrasodium for Cystic Fibrosis First in class, novel compound from Inspire’s discovery efforts Strong intellectual property with composition of matter patent through 2017 Attractive market opportunity with existing CF lung therapies generating > $500 mm in annual revenues* Plan to
Slide 54: Overview of Allergic Rhinitis
Overview of Allergic Rhinitis William E. Berger, MD, MBA Clinical Professor Department of Pediatrics Division of Allergy and Immunology University of California, Irvine
Slide 55: Disclosure
Disclosure The presenter has served as a consultant and clinical investigator for Inspire. The presenter does not own stock or stock options in Inspire Pharmaceuticals.
Slide 56: Allergic Rhinitis: Definition
Allergic Rhinitis: Definition Symptomatic disorder of the nose induced by an IgE-mediated inflammation after allergen exposure of the membranes lining the nose; “hay fever” Seasonal allergic rhinitis (SAR) 1-3 Intermittent Patients may be referred to as “sneezers and runners” Perennial allergic rhin
Slide 57: Rhinitis: Classification
Rhinitis: Classification Classification Non-inflammatory (rhinitis medicamentosa, hormonal, vasomotor) Structural (septal deviation, neoplasia, foreign body, trauma, adenoids, choanal atresia) Inflammatory Non-allergic (NARES, infectious, polyps, associated with- systemic disease) Allergic (SAR, PAR
Slide 58: Allergic Rhinitis: Widespread Impact
Allergic Rhinitis: Widespread Impact More than 50 million people suffer from allergic diseases in the US 1 Allergies are the 6th leading cause of chronic disease in the US 1 AR is the 2nd leading cause of chronic disease in the US2 AR affects 35 million Americans annually 2 10% to 30% of adults 33 A
Slide 59: Allergic Rhinitis: Widespread Impact
Allergic Rhinitis: Widespread Impact Approximately 14 million office visits to healthcare providers were attributed to allergic rhinitis in 20001 Morbidity of AR is significant Financial impact of AR is substantial Productivity loss estimated at >$3 billion per year2 AR medication costs estimated at
Slide 60: Link Between Allergic Rhinitis and Other Chronic Disorders
Link Between Allergic Rhinitis and Other Chronic Disorders Comorbidities1,2 Asthma Allergic rhinoconjunctivitis Sinusitis Otitis media Complications1,3 Sleep-Disordered Otitis Media Breathing Allergic Dentofacial Rhinitis Abnormalities Asthma Sinusitis 1. Spector SL, et al. J Allergy Clin Immunol. 1
Slide 61: Allergic Rhinitis: Therapeutic Approaches
Allergic Rhinitis: Therapeutic Approaches Environmental control Treatments Pharmacotherapy Antihistamines (oral/topical) Decongestants Corticosteroids (oral/topical) Intranasal cromolyn Intranasal anticholinergics Leukotriene receptor antagonists (LTRAs) Allergen immunotherapy
Slide 62: Allergic Rhinitis: Role of Medications
Allergic Rhinitis: Role of Medications Antihistamines Sedating antihistamines* (chlorpheniramine, diphenhydramine) Competitive antagonists of H 1 1-mediated effects Relieve rhinorrhea, pruritus, sneezing, and ocular symptoms Oral, ocular, and intranasal preparations Use is limited by sedation, perfo
Slide 63: Allergic Rhinitis: Role of Medications
Allergic Rhinitis: Role of Medications Decongestants: adrenergic agonists (oral: phenylephrine, pseudoephedrine; topical: phenylephrine, xylometazoline, oxymetazoline) Stimulate receptors to induce local vasoconstriction Decrease blood volume in the nasal mucosa capacitance vessels Reduce blood supp
Slide 64: Role of Medications and Immunotherapy
Allergic Rhinitis: Role of Medications and Immunotherapy Medications Anticholinergic agents 1 (ipratropium bromide) Inhibit parasympathetic transmission to submucosal glands Have low lipid solubility; do not cross blood-brain barrier Leukotriene (LT) modifiers 2 (montelukast) Inhibit LT production a
Slide 65: Allergic Rhinitis Medications: Pharmacologic Activity
Allergic Rhinitis Medications: Pharmacologic Activity Congestion Rhinorrhea Sneezing Nasal Itch Eye Symptoms Inflammation Oral Antihistamines Sedating* – + + + + – Nonsedating/low-sedating † – + + + + ± Intranasal Antihistamines ± + + + – ± Decongestants + – – – – – Intranasal Corticosteroids + + +
Slide 66: Allergic Rhinitis: Emerging Therapies
Allergic Rhinitis: Emerging Therapies Sublingual immunotherapy Anti-IgE therapy New topical nasal antihistamines New topical nasal corticosteroids
Slide 67: Epinastine Multi-Action
Epinastine Multi-Action Inhibits histamine release Inhibits release of inflammatory mediators including cytokines Binds to histamine receptors Inhibits neutrophil activation Inhibits eosinophil activation and cytokine release Inhibits mediator release from basophils Amon U et al. Inflamm Res. 2000;4
Slide 68: Expanding Awareness and Meeting Expectations
Allergic Rhinitis: Expanding Awareness and Meeting Expectations What physicians know… How patients use their medications Nasal steroids not used properly or consistently 64% forget to take their medications 33% felt drugs were ineffective Patient concerns about time to onset of action, safety, cost,
Slide 69: What Adult Patients Want From Their Allergy Medication
What Adult Patients Want From Their Allergy Medication Adults With Allergies 23% 45% 62% 63% 67% 68% 69% Comes in various forms Fewer doses required to control allergy symptoms Provides all-day relief & into next morning all- Wake up with symptoms under control Non-drowsy Maintains effectiveness unt
Slide 70: Patients Look for Allergy Medications To Better Meet Their Needs
Patients Look for Allergy Medications To Better Meet Their Needs Responders (%) 90 80 70 60 50 40 30 20 10 0 70% 38% 51% 81% Interested in New Medications Constantly Try Different Medications Believe Medications Should Be Steroid-Free Would Try a Nasal Spray Harris Interactive online survey of US ad
Slide 71: Factors That Would Encourage Use of a New Nasal Spray
Factors That Would Encourage Use of a New Nasal Spray Steroid-free Can be taken PRN Works quickly Provides long-lasting relief Provides good symptom relief 0% 20% 40% 60% 80% 37% 47% 64% 64% 72% Patients (%) Harris Interactive online survey of US adult allergy patients. Commissioned by the Asthma an
Slide 72: Summary
Summary Emerging allergic rhinitis treatments focus on: Meeting patient needs: Rapid onset, long-lasting & convenient dosing Safety and cost-effectiveness Improving patient adherence/compliance Meeting physician needs: Providing newer, enhanced treatment choices that improve patient quality of life
Slide 73: Thank You
Thank You
Slide 74: Donald J. Kellerman, Pharm.D.
Donald J. Kellerman, Pharm.D. Senior Vice President, Development Inspire Pharmaceuticals Inspire R&D Investor Meeting – March 21, 2006
Slide 75: New Opportunity in Allergic Rhinitis with Proven Molecule
New Opportunity in Allergic Rhinitis with Proven Molecule Licensed U.S. and Canadian rights for rhinitis from Boehringer Ingelheim Known molecule Well-characterized safety Extensive patient experience with oral and ocular forms College of Allergy presentation Proven efficacy following topical admini
Slide 76: Rationale for Nasal Antihistamines for Allergic Rhinitis
Rationale for Nasal Antihistamines for Allergic Rhinitis Clinician interest in having additional options for patients Topical nasal spray can provide quick relief to affected areas; reduced systemic side effects Allergic rhinitis development path is well-defined Large number of patients available to
Slide 77: Advantages of Direct Topical vs. Systemic Administration
Advantages of Direct Topical vs. Systemic Administration Little or no systemic effects Sedation, QT interval, alcohol interaction Amount of drug administered is much less High local concentrations in the nose More effective in blocking triggers of rhinitis Potential for more rapid onset Inspire R&D
Slide 78: Well-Established Profile for Epinastine in Ocular Use
Well-Established Profile for Epinastine in Ocular Use Prevents ocular allergy symptoms by Blocking H1 and H2 receptors Stabilizing mast cells Stopping the progression of pro-inflammatory mediators Important features Low affinity for M3 Soothing upon instillation Rapid relief and sustained duration G
Slide 79: Types of Allergic Rhinitis Indications
Types of Allergic Rhinitis Indications Seasonal Allergic Rhinitis (SAR) -allergens seasonally present Tree, grass, weed pollens Perennial Allergic Rhinitis (PAR) -allergens always present Animal dander, dust mites, molds Non-allergic Rhinitis Perfume, Cigarette smoke Inspire R&D Investor Meeting – M
Slide 80: FDA Guidance on Development Pathway Well Defined
FDA Guidance on Development Pathway Well Defined Written by current FDA Pulmonary Allergy Drug Product Division director Discusses extent of program required Discusses use in pediatric patients Double-blind, placebo-controlled, parallel group studies recommended Double-blind period – 2 weeks for SAR
Slide 81: FDA Guidance on Development Pathway
FDA Guidance on Development Pathway Symptoms are primary efficacy endpoint Instantaneous and reflective symptoms Rhinorrhea, nasal congestion, nasal itching, sneezing Patient symptoms – rated on Diary Cards 0 = absent 1 = mild symptoms 2 = moderate symptoms 3 = severe symptoms Score at least as freq
Slide 82: Types of Allergic Rhinitis Trials
Types of Allergic Rhinitis Trials Traditional 2-week SAR Ragweed August 15—October 15, most of the U.S. Mountain Cedar December 15 – February 15, San Antonio – Austin Trees and Grass April – June, much of U.S. Park setting study Chamber study (Environmental Exposure Unit) Good for both onset of effe
Slide 83: Substantial Experience in Allergy & Respiratory Programs
Substantial Experience in Allergy & Respiratory Programs Development Related Expertise Don Kellerman, Pharm.D. – Flonase®, Beconase®, Techastemizole Richard Evans, Ph.D. – Formulations of Nasacort Amy Schaberg, M.S., R.N – Flonase®, Beconase® Ramesh Krishnamoorthy, Ph.D. – Various formulations of na
Slide 84: Advantages of Intranasal Epinastine Program
Advantages of Intranasal Epinastine Program Strategic expansion of respiratory/ allergy franchise Existing data package of pharmacological and toxicological testing and human experience Extensive internal development and scientific expertise for allergy products Straightforward regulatory pathway Ex
Slide 85: Summary: Intranasal Epinastine
Summary Intranasal Epinastine Enhances focus in the respiratory and allergy therapeutic area Well-known molecule in defined market where Inspire has extensive experience Minimal initial cash investment to in-license asset Plan to commercialize in North America Moving toward IND filing and Phase 2 pr
Slide 86: Benjamin R. Yerxa, Ph.D.
Benjamin R. Yerxa, Ph.D. Chief, Scientific Operations and Alliances Inspire Pharmaceuticals Inspire R&D Investor Meeting – March 21, 2006
Slide 87: Overview of INS50589 Antiplatelet
Overview of INS50589 Antiplatelet Role of platelets in clotting and bleeding Role of P2Y12 receptor in platelet function INS50589 Chemistry and pharmacology Phase 1 results Platelet dysfunction in cardiopulmonary bypass procedures Phase 2 program Strategic partnering Inspire R&D Investor Meeting – M
Slide 88: Role of Platelets in Clotting and Bleeding
Role of Platelets in Clotting and Bleeding activation Platelets Clot Formation Bleeding Problems dysfunction Activation causes: Release of clotting factors and inflammatory mediators Shape change that makes the platelets “stick” to the damaged site Inspire R&D Investor Meeting – March 21, 2006
Slide 89: Role of P2Y12 receptor in platelet function
Role of P2Y12 receptor in platelet function Platelet Cascade Platelet agonists Aspirin Thromboxane A2 ADP Clopidogrel Ticlopidine Activation of GP IIb-IIIa Eptifibatide Abciximab Tirofiban Platelet aggregation Blocking ADP (e.g. P2Y12) on platelets Same mechanism as Plavix® Prevents aggregation Prev
Slide 90: Inhibition of Platelet Aggregation by INS50589
Inhibition of Platelet Aggregation by INS50589 Selective, potent and fully reversible ADP- induced Platelet Aggregation (% of max) 120 100 80 60 40 20 0 -11 -10 -9 -8 -7 -6 -5 log [INS50589], M IC50 Washed Platelets: 13.4 nM Me NH O NH N N ONa N N NaO O P O O O O Ph INS50589 Inspire R&D Investor Mee
Slide 91: INS50589 Phase 1 Trial Objectives
INS50589 Phase 1 Trial Objectives Evaluate the safety and tolerability of a four-hour, continuous infusion of up to four doses of INS50589 in 36 healthy volunteers Evaluate the pharmacokinetics of INS50589 and its major metabolite(s) Evaluate the effects of INS50589 on platelet function Identify a p
Slide 92: Dose Dependent Reduction in Platelet Aggregation
Dose Dependent Reduction in Platelet Aggregation 20 ?M ADP ADP- induced aggregation (% of max) 125 100 75 50 25 0 Dosing period INS50589 All doses 0 240 480 720 960 1200 1440 Time (min) Placebo 0.1 mg/kg/h 0.3 mg/kg/h 1 mg/kg/h 3 mg/kg/h Johnson, et al., ACC 2006 Inspire R&D Investor Meeting – March
Slide 93: INS50589: Linear Pharmacokinetics
INS50589: Linear Pharmacokinetics INS50589 Plasma Concentrations (ng/mL) 100000 10000 1000 100 10 1 Dosing period 0 4 8 12 16 20 24 Time (h) 0.1 mg/kg/h 0.3 mg/kg/h 1 mg/kg/h 3 mg/kg/h INS50589 Plasma Cmax (ng/mL) 40000 30000 20000 10000 0 0 1 2 3 INS50589 (mg/kg/h) Johnson, et al., ACC 2006 Inspire
Slide 94: Phase 1 Trial Conclusions
Phase 1 Trial Conclusions INS50589 was well-tolerated, no treatment-related serious adverse effects were observed and all subjects dosed completed the study Intravenous administration of INS50589 produced a rapid and reversible dose-related inhibition of platelet aggregation Results may support use
Slide 95: Potential Clinical Indications
Potential Clinical Indications Cardiovascular surgery involving cardiopulmonary bypass: Coronary Artery Bypass Graft (CABG) and valve replacements Acute Coronary Syndrome (ACS) Percutaneous Coronary Interventions (PCI) Stroke Clinical conditions where blood is exposed to artificial surfaces such as
Slide 96: Lead Clinical Program: Cardiopulmonary Bypass
Lead Clinical Program: Cardiopulmonary Bypass In the U.S., approximately 450,000 open heart surgeries expected to be performed in 2006* Clinical adverse effects associated with CPB include: Bleeding complications Excessive post-operative blood loss requiring transfusion Embolism Production of vasoac
Slide 97: Normal Blood Vessel
Normal Blood Vessel Inspire R&D Investor Meeting – March 21, 2006
Slide 98: Cardiopulmonary Bypass Circuit Causes Platelet Activation
Cardiopulmonary Bypass Circuit Causes Platelet Activation Inspire R&D Investor Meeting – March 21, 2006
Slide 99: INS50589 Treatment May Protect Platelet Function
INS50589 Treatment May Protect Platelet Function Inspire R&D Investor Meeting – March 21, 2006
Slide 100: Discontinuation of INS50589 May Restore Platelet Function
Discontinuation of INS50589 May Restore Platelet Function Inspire R&D Investor Meeting – March 21, 2006
Slide 101: INS50589 Reduces Post Operative Blood Loss in Dogs
INS50589 Reduces Post Operative Blood Loss in Dogs CABG Surgery in Dogs Percentage of dogs requiring blood transfusion 100 75 50 25 0 Placebo n =7 INS50589 n = 6 Preservation of platelet function and count Reduction of post operative blood loss Reduction of transfusion requirements No effect of drug
Slide 102: INS50589 Phase 2 Trial
INS50589 Phase 2 Trial Randomized, Multicenter, Placebo-Controlled Double-Blind, Parallel Group Study of INS50589 Intravenous Infusion in Subjects Undergoing Coronary Artery Bypass Graft Surgery Involving Cardiopulmonary Bypass Primary Objective: To identify a dose(s) of INS50589 that is well tolera
Slide 103: Strategic Partnering Discussions are Ongoing
Strategic Partnering Discussions are Ongoing Actively seeking partnerships for: INS50589 licensing globally Will consider regional carve outs for the right partner Orally bioavailable candidates included or separate Partnering during Phase 2 allows us to: Continue to build value while simultaneously
Slide 104: Summary: INS50589
Summary INS50589 Potent, selective and reversible P2Y12 antagonist Fast on and fast off kinetics Initial use is in cardiopulmonary bypass surgeries Many other potential indications to explore Plan to commercialize through partnership Phase 2 starting Initiating dose-ranging Phase 2 trial in CABG wit
Slide 105: Inspire
INSPIRE